CD20-CD38+/B

ZeTong Hong1, ZhaoYang Hong2, YaXian Ma1

  • 1Department of Hematology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.

概括

达拉图马布为复发性/耐药性扩散性大B细胞淋巴瘤 (R/R DLBCL) 患者提供了有前途的治疗方法,患者的CD20-CD38+表达,表现出良好的缓解率,并有助于CAR-T治疗过渡.

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K